The CanSinoBIO vaccine is being tested in Pakistan, Mexico, Russia, Argentina and Chile, according to clinical trial registration data, and the company has supply deals with some of those countries, including Mexico. Hassan Abbas, head of the CanSinoBIO's trial at AJ Pharma in Pakistan, said it has already applied to the government for permission to import the vaccine. It was not immediately clear whether the study also looked into the vaccine's efficacy against new and highly transmissible variants first found in South Africa, Britain and Brazil. No serious safety concerns have been raised in the study, Sultan said. In the Pakistani subset, efficacy of the CanSinoBIO vaccine at preventing symptomatic cases was 74.8% and 100% at preventing severe disease, Sultan added.

Source: bd News24 February 08, 2021 15:33 UTC